Table 3 Baseline characteristics of the randomized controlled trial population (mild and moderate myocardial iron loading) vs. open-label combination therapy population (severe myocardial iron loading). Values and abbreviations presented as in table 1.

Number

65

15

-

Age (years)

28.8 ± 4.7

27.8 ± 4.8

0.5

Gender (male)

27 (41.5%)

6 (40.0%)

0.9

Body surface area

1.55 ± 0.15

1.56 ± 0.13

0.8

Heart rate

79 ± 13

97 ± 18

< 0.01

Deferoxamine (mg/kg/day)

40.6 ± 13.5

(5 days/week)

40.7 ± 12.0

(5 days/week)

0.9

CMR measures

Myocardial T2*

12.0 (0.13)

6.0 (0.09)

N/A

Liver T2*

4.5 (0.57)

2.9 (0.67)

0.06

RVEDV (mL)

130.7 ± 32.4

146.7 ± 35.1

0.2

RVESV (mL)

52.4 ± 17.8

76.5 ± 27.6

< 0.01

RVEF (%)

60.6 ± 7.1

49.0 ± 9.4

< 0.01

Echo measures

PAP (mmHg)

21.6 ± 5.2

22.0 ± 5.9

0.8

Blood measures

Hepatitis C positive

49 (75%)

11 (73%)

0.9

Serum ferritin (μg/L)

1472 (0.11)

2057 (0.08)

0.1

BNP (pmol/L)

15.0 (7.1, 28.8)

26.0 (15.6, 40.5)

0.01

Cardiac medication

Any

13 (20%)

7 (47%)

0.03

Digoxin

7 (11%)

4 (27%)

0.1

ACEi/ARB

13 (20%)

7 (47%)

0.03

Diuretics

8 (12%)

4 (27%)

0.2